Market Assessment
Galmed (GLMD) is a small cap ($177M) clinical-stage biopharma developing innovative therapeutics for NASH, a chronic liver disease with high unmet medical needs. The lead investigative drug candidate, aramchol, is pharmacologically and mechanistically designed to negatively modulate hepatic Stearoyl?CoA desaturase, the rate?limiting enzyme in monounsaturated fatty acids synthesis to induce clinically meaningful benefits in NASH. Aramchol offers significant clinical differentiation from other investigative drug candidates for NASH by directly acting on hepatic stellate cells, to improve liver fibrosis and delay its progression to cirrhosis.
NASH in the pediatric population is poorly